Cardiovascular Update For the Clinician: A Symposium by Valentin Fuster

Led by Valentin Fuster, MD, PhD, MACC, Cardiovascular Update For the Clinician will feature expert presentations and panel discussions in each topic area. Immerse yourself in the latest advances in the treatment of cardiovascular disease and learn how to integrate it into your daily practice. Expand your knowledge and expertise with comprehensive updates in patient care.

This year's symposium is focused on the challenges we will face in 2025 across three topic areas: coronary and arterial disease, myocardial and electrical failure, and valvular heart disease and HCM. Plus, don't miss a special fireside chat session with Dr. Fuster.

For busy clinicians and general cardiologists who seek a comprehensive update of new advances in cardiovascular care and how to integrate them into their practices — this is program to attend.

• Session 318. Coronary and Arterial Disease Challenges in 2025 – Evolving New Frontiers
• Session 334. Myocardial and Electrical Failure Challenges in 2025 – Imagenomics and Pharmacology
• Session 350. Valvular Heart Disease and HCM Challenges in 2025 – Understanding and Management
• Session 367. Navigating the Pathway to Leadership: A Fireside Chat With Expert Guides

Pharmacology Program

With the complexity of when and how to use various medications, PharmDs play an important role as members of cardiovascular care team in this era of increasingly coordinated care. The Pharmacology Program will cover hot topics in cardiovascular medicine that are key issues that pharmacists, as well as other health care team members, face in managing complex patients.

The first session will be a case-based session covering the latest evidence for use of GLP-1 agonists in cardiovascular disease including heart failure. The session will include practical tips on obtaining medications (short supply, insurance), medication titration, and adverse effects.

The second session debates the routine use of colchicine in patients with atherosclerotic cardiovascular disease and provides guidance on how to choose from multiple non-statin lipid lowering therapies, and overcoming barriers for patients such as insurance and cost to receive the prescribed therapies.

Join us for an information-packed journey with these dynamic sessions, shaping the future of cardiovascular medicine.

• Session 234. What's the Skinny on GLP-1 Agonists?
• Session 306. Controversies and Choices in Pharmacotherapy for Atherosclerotic Disease